Month: September 2018
Bipartisan congressional leaders in both chambers on Tuesday night unveiled a massive bill aimed at fighting the epidemic of opioid abuse in the United States, capping months of work.
Nevada’s program, called Nevada Health Link, is scheduled to go into operation by 2020. The Affordable Care Act gave states a choice between joining the federal health insurance exchange or administering their own versions, called state-based marketplaces (SBMs). Nevada, along with five other states, had been operating a blended form that placed an independently managed state-based marketplace on the federal tech platform.
Medicaid Spending Hit $581B in 2016. Here’s How Its Projected to Grow Over the Next Decade
Medicaid provided healthcare coverage to 72.2 million people in fiscal year 2016, an increase of 3.1% over 2015.
Air ambulance rides are literal lifesavers. But how much should they cost? In the ongoing, crowdsourced “Bill of the Month” investigation, Kaiser Health News and NPR received more than a dozen bills from people around the country on the hook for medevac helicopter rides that ranged from $28,000 to $97,000.
States serve as “laboratories of democracy,” as U.S. Supreme Court Justice Louis Brandeis famously said. And states are also labs for health policy, launching all kinds of experiments lately to temper spending on pharmaceuticals.
A proposed rule from the White House would make it harder for legal immigrants to get green cards if they have received certain kinds of public assistance — including Medicaid, food stamps and housing subsidies. Green cards allow them to live and work permanently in the United States.
More drug companies raised their prices in the past year than cut them, according to an analysis by The Associated Press published on Monday.
Spending on medical services for people enrolled in employer-sponsored health plans increased 44% between 2007 and 2016, according to researchers from the Health Care Cost Institute (HCCI).
The double whammy of rising healthcare costs and an aging population could cause a ripple of negative impacts across the U.S. economy.
Gilead Sciences Inc. will sell cheaper versions of its blockbuster hepatitis C drugs, the original versions of which sparked widespread debate about U.S. pharmaceutical costs when they were introduced at a price of more than $1,000 a pill.